Sanofi Understands Its Problem, but Still Lacks Solutions
Dow Jones07-31 18:34
1033 GMT - The first thoughts from Sanofi's new CEO Belen Garijo suggest the company understands the problem it faces to replace blockbuster sales of its Dupixent drug, but still needs to come up with solutions, UBS analysts say in a research note. Understanding the problem is a real milestone, it is better than defending a pipeline of mediocre assets, the analysts say. But this means Sanofi investors will have to wait to see what solutions the company finds and how it implements them, they add. "In our view, expecting answers this early was unrealistic," UBS says. The company hinted at a more strategic update alongside third-quarter results, the analysts say. Shares rise 2.1%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments